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Platelet reactivity in patients with impaired renal function receiving dual
antiplatelet therapy with clopidogrel or ticagrelor
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BACKGROUND Suboptimal platelet inhibition still represents an impor-
tant challenge, especially for patients undergoing percutaneous coronary
interventions (PCI). Chronic kidney disease (CKD) is a common comor-
bidity of patients with coronary artery disease, and may potentially inﬂu-
ence platelet reactivity. So far only few studies have assessed the role of
CKD on response to dual antiplatelet therapy with conﬂicting results.
Therefore, the aim of our study was to evaluate the impact of CKD on
platelet function in patients treated with dual antiplatelet therapy (DAPT)
after a recent acute coronary syndrome or PCI.
METHODS Patients treated with DAPT (ASA + clopidogrel or tica-
grelor) for an ACS or elective patients undergoing PCI were scheduled
for platelet function assessment at 30-90 days post-discharge. Platelet
function was assessed by whole blood impedance aggregometry
(Multiplate- Roche Diagnostics AG), HRPR was considered for ASPI
test >862 AU*min (for ASA) and ADP test values >417 AU*min (for
ADP-antagonists). Chronic renal failure was deﬁned as an estimated
glomerular ﬁltration rate of 60 ml/min/1.73m2 or less, calculated by
applying MDRD (Modiﬁcation of Diet in renal Disease) formula.
RESULTS Our population included a total of 537 patients of which 308
(57.3%) received ASA and clopidogrel and 229 (42.6%) received ASA
and ticagrelor. Patients with renal failure at baseline (101 out of 537,
18.8%) were older, with higher prevalence of history of hypertension,
myocardial infarction and coronary artery bypass graft surgery.
Moreover, they had a lower ejection fraction at baseline and were
more often in therapy with diuretics, but less often with statins at
admission. They had lower haemoglobin and higher glycated hae-
moglobin. HRPR was observed in 1.5% of patients treated with ASA
with no difference according to renal function (p ¼ 0.18). HRPR for
ADP-antagonists was observed in 23.7% of patients, with no difference
according to renal function (p ¼ 0.50). This result was conﬁrmed both
with clopidogrel (31.9% versus 38%, p ¼ 0.41) and ticagrelor (13.1%
versus 10.8%, p ¼ 0.99), also after correction for all baseline con-
founders (clopidogrel: adjusted OR [95%CI] ¼ 1.26 [0.60 - 2.63], p ¼
0.54) (ticagrelor: adjusted OR[95%CI] ¼ 0.95 [0.54 - 1.65], p ¼ 0.84).
The absence of association between renal function and platelet reac-
tivity was conﬁrmed at linear regression analysis both with clopi-
dogrel (r ¼ -0.04, p ¼ 0.52) and ticagrelor (r ¼ 0.006, p ¼ 0.92).
CONCLUSIONS In patients receiving dual antiplatelet therapy,
chronic renal failure did not inﬂuence ADP-mediated platelet reac-
tivity, with both ticagrelor or clopidogrel. No inﬂuence of chronic
renal failure was found on the effectiveness of ASA.
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BACKGROUND Platelet Inhibition and Patient Outcomes Trial (PLATO
trial) demonstrated that aspirin and ticagrelor were superior to aspirin
and clopidogrel in reducing thrombotic complications. Continuous
infusion of IIb/IIIa inhibitors (GPI) was used in 40% of patients with
ticagrelor in the PLATO trial. However, the inhibition of platelet ac-
tivity with ticagrelor starts rapidly and it is questionable whether
continuous infusion of GPI with ticagrelor is needed, We, therefore,
compared the impact of GPI bolus only vs. bolus and short infusion
of GPI with ticagrelor on percent inhibition of platelet aggregation
(%IPA) and outcome in patients with non-ST-segment myocardial
infarction (NSTEMI).METHODS A total of 70 patients with NSTEMI were randomized to
ticagrelor 190 mg loading and eptiﬁbatide bolus-only (TEP) vs. tica-
grelor loading and eptiﬁbatide bolus plus 2 h infusion(TEPI) admin-
istrated before stenting. Light transmission aggregometry was
performed and %IPA was calculated at baseline, 2 h, 6 h, and 24 h
using ADP, TRAP, collagen, and arachidonic acid (AA). Cardiac en-
zymes, hemoglobin and hematocrit were measured at baseline and 24
h. The event rates were determined at 30-day follow-up.
RESULTS In patients randomized to TEP vs. TEPI, there were no
signiﬁcant difference in the %IPA values at 2 h and 6 h with ADP 5mM
(100%  0.01 vs. 99%  0.25 and 99%  2.4 vs. 99%  1.2, respectively)
and with ADP 20 mM (Fig. 1), as well as with collagen. However, %IPA
was lower at 24 h (still >60) compared with that at 2 h and 6 h. Percent
IPA with TRAP 10 or 20 mM was higher at 6 h in patients randomized to
TEPI vs. TEP (87%  13 vs. 74%  17; P<0.01, respectively).This had no
bearing on outcomes since ADP was highly inhibited by ticagrelor at 6
h. There were no signiﬁcant differences in troponin or hemoglobin
levels among the groups. During follow-up, there was no stent
thrombosis or myocardial infarction.
CONCLUSIONS Percent IPA values with ADP and collagen were not
signiﬁcantly different comparing ticagrelor with eptiﬁbatide bolus
only vs. ticagrelor and eptiﬁbatide bolus plus 2 h infusion. Eptiﬁbatide
bolus only highly inhibited platelets aggregation while allowing
bridging to the antiplatelet effect of ticagrelor and circumventing the
need for continuous eptiﬁbatide infusion. There was no signiﬁcant
difference in bleeding or MI between the 2 groups.
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BACKGROUND Uninterrupted warfarin with intra-procedural heparin
is a commonly used anticoagulation strategy during atrial ﬁbrillation
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if novel oral anticoagulants (NOAC) had comparable efﬁcacy and
safety to that of warfarin for AF ablation.
METHODS PubMed, Google Scholar and EBSCO were queried for
studies comparing NOACS and warfarin use for peri-procedural AF
ablation. Data on thromboembolic events (TE), major and minor
bleeding was then extracted from the included studies. Meta-analysis
was carried out using Mantel-Haenszel random effects risk ratio (RR)
model.
RESULTS A total of 26 studies with 11,298 patients were included in
this analysis. Warfarin and NOACS were used in 7496 and 3802 pa-
tients respectively. TE occurred in 0.42% and 0.29% of the NOAC and
Warfarin groups, respectively. The incidence of major bleeding was
similar and occurred in 1.2% in both groups. The risk of TE for the
NOAC group was 1.28 (95% CI 0.56 – 2.96, p¼0.56) compared to
warfarin. There were no subgroup differences with the use of Apix-
aban, Dabigatran or Rivaroxaban. The risk of major bleeding was also
similar between the two groups (RR 0.95, 95% CI 0.59 – 1.53, p¼0.82).
Minor bleeding occurred in 3.4% and 4.2% in the NOAC and warfarin
groups respectively. Subgroup exclusion sensitivity analyses of indi-
vidual drugs of apixaban, dabigatran and rivaroxaban did not alter the
above outcomes. The heterogeneity between the included studies was
extremely low (I2¼0%). Publication bias was assessed using funnel
plot and showed minimal bias.
CONCLUSIONS The results of our study suggest that uninterrupted
NOAC and warfarin use with intra-procedural heparin use for AF
ablation have low and similar risk for TE and major bleeding. However
the risk of minor bleeding is decreased by 27% in the NOAC group.
Further randomized studies are needed to determine the beneﬁt with
the use of NOACS.
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Sang-Ho Park,1 Seung-Woon Rha,2 Ung Jun,1 Byoung Geol Choi,2
Se Yeon Choi,2 Jae Kyeong Byun,2 Jin oh Na,2 Cheol Ung Choi,2
Hong Euy Lim,2 Jin Won Kim,2 Eung Ju Kim,2 Chang Gyu Park,2
Hong Seog Seo,2 Dong Joo Oh2
1Cardiology Department, Soonchunhyang University Cheonan
Hospital, Cheonan, Korea, Republic of; 2Cardiovascular Center, Korea
University Guro Hospital, Seoul, Korea, Republic of
BACKGROUND To date, there are limited data regarding combination
antiplatelet regimen (dual; asprin plus clopidogrel versus triple;
aspirin plus clopidogrel plus cilostazol) following percutaneous
transluminal angioplasty (PTA) in patients (pts) with symptomatic
peripheral arterial disease (PAD).
METHODS We investigated the 475 consecutive PAD pts underwent
PTA from September 2004 to December 2013. One-year clinicaloutcomes of symptomatic PAD pts treated with dual antiplatelets
(DAP, n¼241) were compared with those of PAD pts with triple anti-
platelets (TAP, n¼234). Cilostazol was maintained at least more than 1
month following PTA.
RESULTS At baseline, there were no signiﬁcant differences in
clinical characteristics including age, gender, hypertension, dysli-
pidemia, cerebrovascular accident (CVA), coronary artery disease,
myocardial infarction, congestive heart failure between the two
groups except diabetes, chronic renal insufﬁciency (CRI), and
smoking; the DAP group had higher incidence in diabetes and CRI,
whereas the TAP group had higher incidence of smoking. The
distribution of clinical symptom was as follows; 1: Claudication was
19.5% in DAP and 38% in TAP (p¼0.402), 2: resting pain was 5.4%
in DAP and 22.6% in TAP (p<0.001), 3: Wound was 72.2% in DAP
and 53.0% in TAP (p<0.001). 4: Gangrenous change was 27.4% in
DAP and 20.1% in TAP (p¼0.062). There was a trend toward higher
incidence of repeat PTA primarily due to higher trend of target
extremity revascularization (TER) at 1 year in the TAP group. This
result probably translated into trend toward lower incidence of
target extremity surgery (TER), particularly below-the-ankle
amputation in the TAP group (Table). There was no signiﬁcant
difference in 1-year major clinical outcomes including total death,
cardiac death, acute myocardial infarction (AMI), percutaneous
coronary intervention (PCI), CVA, and major adverse
cerebrocardiovascular events (MACCEs) between the two groups
(Table).
CONCLUSIONS In our study, despite of similar incidence of individ-
ual and composite hard endpoints between the DAP and TAP regimen
following PTA, the use of TAP was associated with higher trend of
repeat PTA and subsequent lower incidence of amputation at 1 year.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
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BACKGROUND The effectiveness of dual antiplatelet therapy (DAPT)
for secondary prevention in speciﬁc patient’s subsets is unclear. We
sought to evaluate the effectiveness of longer durations of DAPT in
women and men.
METHODS We included gender-speciﬁc effect estimates from ran-
domized controlled trials (RCTs) testing DAPT in patients with CAD.
Study groups were classiﬁed as: shorter DAPT (S-DAPT), deﬁned as
